Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapsone Gel, 5 percentage

Mumbai, June 29: Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration  for its Abbreviated New Drug Application  Dapsone Gel, 5percentage.

The approved ANDA is therapeutically equivalent to the reference listed drug product , Aczone Gel, 5 percentage, of Almirall, LLC. Dapsone Gel is indicated for the topical treatment of acne vulgaris. Refer label for a detailed indication.

Alembic has a cumulative total of 244 ANDA approvals  from USFDA.

Leave a Reply

Your email address will not be published. Required fields are marked *